China (Mainland)
Assessedsupplier
Fesoterodinefumarate CAS NO.286930-03-8
- Min.Order: 1 Gram
- Payment Terms: T/T,Other
- Product Details
Keywords
- (R)-Fesoterodine Fumarate
- 286930-03-8
- 99% purity
Quick Details
- ProName: Fesoterodinefumarate
- CasNo: 286930-03-8
- Molecular Formula: C30H41NO7
- Appearance: White Solid
- Application: intermediate
- DeliveryTime: large stock
- PackAge: According to the need to packing
- Port: Shanghai
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99% purity
- Storage: sealed,dry,low temperature
- Transportation: air,sea and courier
- LimitNum: 1 Gram
- Grade: Industrial Grade,Pharma Grade,Electron...
Superiority
Fesoterodinefumarate Basic information
Product Name: Fesoterodinefumarate
Synonyms: Fesoterodine maleate;2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate;Propanoic acid, 2-methyl-, 2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) (salt);Spm 8272;Toviaz;Unii-eos72165S7;Fesoterodinefumarate;(R)-Fesoterodine Fumarate
CAS: 286930-03-8
MF: C30H41NO7
MW: 527.65
EINECS: 639-689-3
Product Categories: Toviaz;Amines;Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File: 286930-03-8.mol
Details
Fesoterodinefumarate Usage And Synthesis
Chemical Properties White Solid
Uses Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. Fesoterodine fumarate (Toviaz) is used to treat the symptoms of overactiv
Uses (R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS).
Uses (R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS). It is very similar to Tolterodine (T535800).
Clinical Use Antimuscarinic:
Symptomatic treatment of urinary incontinence, frequency or urgency
Drug interactions Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic side effects with disopyramide.
Antifungals: dose reduction advised with itraconazole and ketoconazole.
Antivirals: dose reduction advised with atazanavir, indinavir, ritonavir and saquinavir.
Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers (e.g. carbamazepine, rifampicin, phenobarbital, phenytoin, St John's Wort) is not recommended.
Co-administration of a potent CYP2D6 inhibitor may result in increased exposure and adverse events. A dose reduction to 4 mg may be needed'
See 'Other information'
Metabolism Molecular weight (daltons) 527.7 % Protein binding 50 (metabolite) % Excreted unchanged in urine 70 (as metabolites) Volume of distribution (L/kg) 169 Litres Half-life - normal/ESRF (hrs) 7 / -